

Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $8.76
Latest analyst grade actions
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 61.78 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 40.18 | Oscillator | Neutral |
| Williams %R (14) | -52.38 | Oscillator | Neutral |
| MACD (12, 26, 9) | 0.84 (Hist -0.06) | Oscillator | Sell |
| Average Directional Index (14) | 37.44 (+DI 30.9 / -DI 14.5) | Trend | Strong Buy |
| EMA 20 | 7.24 | MA | Strong Buy |
| SMA 20 | 7.61 | MA | Strong Buy |
| EMA 50 | 5.91 | MA | Strong Buy |
| SMA 50 | 5.17 | MA | Strong Buy |
| SMA 200 | 5.08 | MA | Strong Buy |
TTM vs. 5-year historical average (annual ratios)
| Metric | CD | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -97.1x | -34.2x · sector 20.4x | Discount |
| Forward P/E | — | — | n/a |
| Price / Book | 14.6x | 7.1x | Elevated |
| Price / Sales | 301.9x | 182.7x | Elevated |
| EV / EBITDA | -180.1x | -59.0x | Elevated |
| Return on equity | -16.5% | — | Weak |
| Gross margin | 63.6% | -51.4% | Below hist. |
| Debt / Equity | 0.02 | 0.21 | Conservative |
| Piotroski / Altman Z | 5/9 | Z 158.18 | Safe zone |
Discounted cash flow model
FY2024 · 10-K disclosure
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Oct 6, 2026 | 2026-10-06 14:05:49 | View |
| 8-K | Sep 24, 2026 | 2026-09-24 13:45:22 | View |
| 3 | Sep 1, 2026 | 2026-09-01 11:15:50 | View |
| 3 | Sep 1, 2026 | 2026-09-01 11:12:02 | View |
| 144 | Aug 28, 2026 | 2026-08-28 10:53:33 | View |
| 8-K | Aug 25, 2026 | 2026-08-25 16:40:26 | View |
| 8-K | Aug 21, 2026 | 2026-08-21 16:05:31 | View |
| 424B5 | Aug 21, 2026 | 2026-08-21 12:18:55 | View |
| 10-Q | Aug 14, 2026 | 2026-08-14 16:16:45 | View |
| 8-K | Aug 11, 2026 | 2026-08-11 16:05:16 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 24, 26 | Mcgillis Gregory | director: | 0 | — | |
| Aug 24, 26 |
| Li Jialin |
| director: |
| 0 |
| — |
| May 19, 26 | Daye Wilfred Zhongkei | director, officer: CSO | S-Sale | 2,000 @ $9.36 | $18.72K |
| May 20, 26 | Daye Wilfred Zhongkei | director, officer: CSO | S-Sale | 4,000 @ $9.66 | $38.62K |
| May 21, 26 | Daye Wilfred Zhongkei | director, officer: CSO | S-Sale | 2,000 @ $9.33 | $18.66K |
| Mar 18, 26 | Daye Wilfred Zhongkei | director, officer: Chief Strategy Officer | 0 | — |
| Mar 18, 26 | Zhang Yukuan | officer | 0 | — |
| Mar 18, 26 | Nobel Sven Peter Emanuel | director: | 0 | — |
Stock news · updated daily
U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZIÂ (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's DiseasePR News
XP (NASDAQ: XP - Get Free Report) and Chindata Group (NASDAQ: CD - Get Free Report) are both finance companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability. Profitability This table compares XP and Chindata Group's net
SKYRIZIÂ (risankizumab) and RINVOQÂ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2
New York, NY, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Chaince Securities, LLC (“Chaince”), a FINRA-registered broker-dealer and wholly owned subsidiary of Chaince Digital Holdings Inc. (NASDAQ: CD), today announced that it has been engaged as the exclusive sales agent for the at-the-market (“ATM”) equity offering program of CL Workshop Group Limited (NASDAQ: NWGL) (the “Company”), a British Virgin Islands-incorporated holding company headquartered in Macau whose operations are conducted in Peru, France and Macau through its operating subsidiaries and which is principally engaged in forest management, harvesting, and the processing, manufacturing and distribution of wood products.
Chindata Group (NASDAQ: CD - Get Free Report) and B. Riley Financial (NASDAQ: RILY - Get Free Report) are both small-cap finance companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends. Earnings and Valuation This table compares
New SKYRIZIÂ (risankizumab-rzaa) and RINVOQÂ (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel DiseasePR NewswireNOR
Chindata Group Holdings Limited (NASDAQ: CD - Get Free Report)'s share price gapped down prior to trading on Friday. The stock had previously closed at $10.91, but opened at $10.60. Chindata Group shares last traded at $7.24, with a volume of 108,886 shares traded. Analyst Ratings Changes A number of equities analysts have issued reports on
New York, NY, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Chaince Securities, LLC (“Chaince”), a FINRA-registered broker-dealer and wholly owned subsidiary of Chaince Digital Holdings Inc. (NASDAQ: CD), today announced that it has been engaged as the exclusive sales agent for the at-the-market (“ATM”) equity offering program of Magic Empire Global Limited (NASDAQ: MEGL) (the “Company”), a British Virgin Islands-incorporated holding company whose operations are conducted in Hong Kong through its operating subsidiaries and which is principally engaged in corporate finance advisory services. The engagement is made pursuant to an At-the-Market Offering Agreement dated September 30, 2026 (the “Sales Agreement”), under which the Company may offer and sell, from time to time, Class A ordinary shares of the Company (the “Shares”) having an aggregate offering price of up to US$100 million through Chaince, as sales agent.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 14, 2026 | — | -0.01 | — | $463.2K |
| May 14, 2026 | — | -0.03 | — | $1.40M |
| Aug 31, 2023 | 0.39 | 0.71 | Beat 82.1% | $246.2K |
| May 31, 2023 | 0.31 | 0.85 | Beat 174.2% | $80.35M |
| Nov 22, 2022 | 0.38 | -0.36 | Miss -194.7% | $783.1K |
| Jan 5, 2022 | 0.20 | -0.04 | Miss -120.0% | $664.2K |